Directive 2001/83/EC, as amended, provides for measures to prevent the entry into the legal supply chain of falsified medicinal products by requiring the placing of safety features consisting of a unique identifier and an anti-tampering device on the packaging of certain medicinal products for human use for the purposes of allowing their identification and authentication.
Recital 1, Regulation (EU) 2016/161
Judgment of the Court (Fifth Chamber) of 17 November 2022. Merck Sharp & Dohme BV and Others v Abacus Medicine A/S and Others.Decision
Recitals 1, 11, 12 and 15 of Delegated Regulation 2016/161 state: Directive [2001/83] provides for measures to prevent the entry into the legal supply chain of falsified medicinal products by requiring the placing of safety features …
17 Nov 2022 · 62020CJ0224
Judgment of the Court (Fifth Chamber) of 17 November 2022. Bayer Intellectual Property GmbH v kohlpharma GmbH.Decision
Recitals 1, 11, 12 and 15 of Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplementing Directive 2001/83 (OJ 2016 L 32, p. 1), state: Directive [2001/83] provides for measures to prevent the entry into the legal supply …
17 Nov 2022 · 62020CJ0204
Judgment of the Court (Fifth Chamber) of 17 November 2022. Novartis Pharma GmbH v Abacus Medicine A/S.Decision
Recitals 1, 11, 12 and 15 of Delegated Regulation 2016/161 state: Directive [2001/83] provides for measures to prevent the entry into the legal supply chain of falsified medicinal products by requiring the placing of safety features …
17 Nov 2022 · 62020CJ0147